Compare Deutsche Bank AG (DB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Mesoblast Limited — how do they compare? Deutsche Bank AG trades at $35.81 (market cap $67.54B), while Mesoblast Limited trades at $16.95 (market cap $2.09B). The key difference: Deutsche Bank AG is far larger — about 32.3× Mesoblast Limited's market cap, and Deutsche Bank AG pays a 3.3% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DB | MESO | |
|---|---|---|
Market Cap | $67.54B | $2.09B |
Sector | Financials | Technology |
52-Week High | $40.33 | $20.96 |
52-Week Low | $28.37 | $10.96 |
Dividend Yield | 3.3% | — |
Enterprise Value | — | $2.10B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
